Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Open Access
- 3 June 2020
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (6), 1721
- https://doi.org/10.3390/jcm9061721
Abstract
Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the era of targeted therapy, the great advances in the understanding of programmed death-ligand 1 (PD-L1) upregulation in cancer cells, which is responsible for tumor immune escape, have contributed to the increasing interest in immune checkpoint inhibitors as a promising strategy for the treatment of several refractory solid malignancies, including endometrial cancer. Several clinical trials have investigated the efficacy and safety of immune checkpoint inhibitors in endometrial cancer, which already led to the approval of the anti-programmed cell death protein 1 (anti-PD-1) antibody pembrolizumab as a satisfactory alternative for selected patients with unresectable or metastatic disease. As the future of cancer treatment will probably rely on combination therapy strategies, currently, innovative ongoing trials are exploring the potential role of immune checkpoint inhibitors associated with chemotherapy, radiotherapy, and other targeted therapies. Moreover, further research is warranted to discover new specific biomarkers that can accurately predict the response to immunotherapy.Keywords
This publication has 57 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyJournal of Leukocyte Biology, 2013
- Molecular mechanisms of T cell co-stimulation and co-inhibitionNature Reviews Immunology, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Direct activation of antigen-presenting cells is required for CD8+T-cell priming and tumor vaccinationProceedings of the National Academy of Sciences of the United States of America, 2011
- Mechanisms of costimulationImmunological Reviews, 2009
- Systematic Review of Microsatellite Instability and Colorectal Cancer PrognosisJournal of Clinical Oncology, 2005
- Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classificationVirchows Archiv A Pathological Anatomy and Histopathology, 2004
- Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon CancerThe New England Journal of Medicine, 2003
- Two pathogenetic types of endometrial carcinomaGynecologic Oncology, 1983